Mar­tin Shkre­li's old com­pa­nies se­cure $650,000 deal to sell Dara­prim amid bank­rupt­cy

Dara­prim, the an­ti-malar­i­al and an­ti-par­a­sitic at the heart of “Phar­ma Bro” Mar­tin Shkre­li’s price-goug­ing no­to­ri­ety, is chang­ing hands once again.

Vy­era Phar­ma­ceu­ti­cals — for­mer­ly known as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER